Novel approach for analyzing NF-kB pathway activity in primary CNS lymphoma
Project/Area Number |
18K16565
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 56010:Neurosurgery-related
|
Research Institution | Yokohama City University |
Principal Investigator |
Nakamura Taishi 横浜市立大学, 附属市民総合医療センター, 助教 (60771615)
|
Project Period (FY) |
2018-04-01 – 2022-03-31
|
Project Status |
Discontinued (Fiscal Year 2021)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 中枢神経原発悪性リンパ腫 / DNAメチル化 / NF-kB pathway / リン酸化p65 / PCNSL / TERT / NF-κb / DNA methylation / テロメア伸長 / テロメラーゼ非依存性テロメア伸長 / 薬剤感受性 / リンパ腫 |
Outline of Final Research Achievements |
In this project, we obtained primary CNS lymphoma (PCNSL) tumors and the patients’ clinical data. We found out a key subdomain of p65 in constitutive NF-kB pathway activation using established PCNSL cell-line. We focused on phosphorated p65 distribution and expression level in PCNSL tissues. We combined genome-wide methylation data, multiple mutation status and analyzed correlation between these molecular status and clinical prognosis. Though resulted in no clinical impact of phosphorated p65 distribution and expression level to PCNSL patient prognosis in the primary analysis, the phosphorated p65 were activated in infiltrating zone in the tumor. So we are conducting additional analysis to find out clinical impact of it.
|
Academic Significance and Societal Importance of the Research Achievements |
PCNSLにおいてNF-kB pathwayが腫瘍において恒常的に活性化し,なかでもcanonical pathwayに依存している結果を得た上でそのサブドメインであるp65のリン酸化状態の発現が核内移行し標的遺伝子を活性化させることを明らかにした。集積した症例についてNF-kB pathwayの恒常的活性化及びリン酸化p65の発現がPCNSLの予後を規定していないことが示された。一方で、壊死や腫瘍境界部分での活性は腫瘍の浸潤性と関与しておりより詳細な発現評価が臨床においてもインパクトを示すことが示された。
|
Report
(3 results)
Research Products
(6 results)
-
[Journal Article] 研究 ESHAP二次化学療法の再発中枢神経系原発悪性リンパ腫に対する後方視的検討2018
Author(s)
Nagao, K. Nakamura, T. Tateishi, K. Sato, H. Shimizu, N. Suenaga, J. Murata, H. Kanno, H. Yamamoto, T.
-
Journal Title
Neurological Surgery 脳神経外科
Volume: 46
Issue: 7
Pages: 575-581
DOI
ISSN
0301-2603, 1882-1251
Year and Date
2018-07-10
Related Report
Peer Reviewed
-
-
-
-
-